The Muscle Question Nobody Asks Before Choosing Zepbound or Wegovy

*Medically reviewed by *

This article is for information only and is not medical advice — talk to your prescriber before changing your medication, dose, diet, or exercise plan.

Both Zepbound (tirzepatide) and Wegovy (semaglutide) cause weight loss that includes some lean mass, and body-composition sub-studies suggest that, without a plan, roughly a quarter to a third of the weight lost can be muscle. Because Zepbound tends to produce greater total weight loss (about 20% versus 14% in head-to-head data), it can mean more absolute muscle loss — but the proportion looks broadly similar, and it's largely preventable. Hit a protein floor of about 1.2–1.6 g/kg/day, do resistance training two to three times a week, and track body-fat %, not just the scale.

That's the short version. The longer version is where the two drugs actually differ, why "more weight lost" isn't the same as "worse muscle ratio," and exactly how to protect and measure your lean mass — which is the part no comparison page seems to finish.

Zepbound vs Wegovy muscle loss: what the trials actually show

Start with the mechanism, because it explains why muscle is even on the table. Neither drug attacks muscle directly. Wegovy is a GLP-1 receptor agonist; Zepbound acts on both GLP-1 and GIP receptors. What they share is appetite suppression and slowed gastric emptying, per the Novo Nordisk prescribing information for Wegovy and the Eli Lilly prescribing information for Zepbound. Eat markedly less, lose weight quickly, and some of what comes off is lean tissue — that's true of almost any large, rapid energy deficit, not something unique to these drugs.

The clearest head-to-head data comes from SURMOUNT-5, published in the New England Journal of Medicine in 2025. Over 72 weeks in adults with obesity or overweight (without diabetes), tirzepatide produced an average weight loss of about 20.2% versus 13.7% for semaglutide. Zepbound won on total weight lost. That headline is well established.

What SURMOUNT-5 was not designed to headline is the fat-versus-lean split. For that, the field leans on DXA and imaging sub-analyses from the pivotal trials: the fat-mass and lean-mass breakdown reported in body-composition sub-studies of STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide), both published in NEJM, and MRI-based muscle-composition work in the SURPASS program on tirzepatide. Read together, these suggest that a meaningful share of weight lost on either agent is lean mass, with the proportion broadly comparable between the two — not a clean win for one drug.

The honest nuance: notably, sarcopenia was not reported as a safety signal across the SURMOUNT obesity trials. So the takeaway is "protect your muscle," not "panic about it."

Percentage vs absolute: why "more weight lost" can still mean "more muscle lost"

Here's the distinction that trips people up. Imagine two people who each lose weight where 25% of the loss is lean mass. If one loses 15 kg and the other loses 23 kg, the ratio is identical — but the second person loses more actual kilograms of muscle. That's the Zepbound-versus-Wegovy situation in miniature: greater total loss can carry more absolute lean-mass loss even when the percentage looks similar.

Does that make Zepbound the "worse" choice for muscle? Not really — because absolute lean loss is exactly what a protein floor plus resistance training is designed to blunt. The bigger the total loss, the more the prevention plan matters, not the more you should avoid the more effective drug. Which drug fits you is a prescriber decision (more on that below); the muscle plan is the same either way.

How much muscle you actually lose (and the "skinny fat" risk)

Across body-composition reviews of rapid weight loss — including work summarized in JAMA and covered by outlets like Medical News Today — a common estimate is that, without resistance training and adequate protein, somewhere in the range of a quarter to 40% of total weight lost can come from lean mass. Treat that as a hedged range from body-composition sub-analyses, not a fixed law; individual results vary with age, starting muscle, activity and diet.

Why does GLP-1 weight loss stack the deck? Two forces compound. First, the loss is often fast, and faster loss tends to pull more from lean tissue. Second, appetite suppression makes it genuinely hard to eat enough protein — the exact nutrient that defends muscle. Lose weight quickly while under-eating protein and you can end up lighter on the scale but with a higher body-fat percentage than you'd expect: the "skinny fat" GLP-1 outcome people describe. That matters beyond looks — lean mass is metabolically active, and preserving it supports the resting metabolic rate that makes weight maintenance easier once you reach it.

The point isn't fear. It's that muscle loss is the predictable, addressable side of these drugs — and the two levers that address it are protein and resistance training.

How much protein to protect muscle on Zepbound or Wegovy

For general health, protein needs sit around 0.8 g/kg/day. During active weight loss, that's widely considered too low to defend muscle. Muscle-preservation and sports-nutrition sources — including the ISSN position stand on protein and intake — point to a floor closer to 1.2–1.6 g/kg/day, with a higher range of about 1.6–2.2 g/kg/day cited for people who are actively strength-training and want maximum lean-mass preservation.

Turn that into your grams. A 90 kg (about 198 lb) person lands roughly at:

• 1.2 g/kg → ~108 g/day
• 1.6 g/kg → ~144 g/day

Then spread it out. Muscle-protein synthesis responds best to protein delivered across the day rather than dumped into one meal, and roughly 20–40 g of quality protein per meal is a commonly cited effective range. Three to four meals of 30–40 g gets most people to their floor without turning eating into a math problem. Confirm your own number with a dietitian or prescriber — kidney conditions and other factors can change the target.

The titration trap. Nausea is the most common GI side effect of both drugs, and per the Zepbound and Wegovy prescribing information it clusters around dose increases and typically eases once you settle on a stable dose. Titration — stepping the dose up gradually — is the main tolerability lever. The catch: nausea suppresses appetite hardest right when you're increasing the dose, which is exactly when protein intake tends to dip. The practical move is to front-load protein on your stable-dose days and go gentle on dose-increase days, rather than fighting your stomach. If nausea is severe or persistent, that's a prescriber conversation, not something to push through.

In Tiro, you can track your daily protein floor against a target calculated from your weight — so you hit roughly 1.2–1.6 g/kg without counting calories, and see per-meal where you're short. You can also set your titration and next-dose reminders so you can plan protein around your stable-dose days.

Resistance training: the other half of muscle preservation

Protein gives muscle the raw material; resistance training gives it the reason to stay. In studies of weight loss, combining adequate protein with regular strength training preserves the large majority of lean mass compared with dieting alone — the two work together, and neither fully substitutes for the other.

You don't need a complicated program. Two to three resistance sessions a week, hitting the major muscle groups, with gradual progressive overload (a little more weight, reps, or sets over time) is the durable pattern most guidance converges on. Bodyweight work, resistance bands, dumbbells or machines all count. On a GLP-1, energy can be lower and hydration matters, so build up sensibly and clear a new exercise plan with your clinician if you have heart, joint or other conditions. Applied consistently on either drug, this is the single biggest lever besides protein.

How to measure muscle loss (stop trusting the scale)

The scale has one fatal flaw for this job: it can't tell fat from muscle. A pound is a pound. If you're doing everything right, you might even see the scale stall while your body composition improves — fat down, muscle steady. Judge progress by what the scale can't see. Here's a practical hierarchy:

1. Body-fat % trend. The single most useful number, because it separates fat from lean. Watch the direction over weeks, not any one reading.
2. Tape measurements at fixed sites. Measure the waist (at the navel), hips (at the widest point), thigh (mid-thigh), upper arm (mid-bicep), and chest. Same spots, same tension, same time of day.
3. Progress photos. Front, side and back, same lighting and posture, monthly. The mirror lies day to day; a photo timeline doesn't.
4. A monthly 3D body scan. A scan can estimate a lean-versus-fat trend over time so you can see whether the weight leaving is the weight you want gone.

Two rules make all of this work. Re-measure on a schedule — monthly, under the same conditions (morning, similar hydration) — and trust the trend, not the reading. A single measurement is noise; three in a row is a signal.

Curious whether you're losing fat or muscle? Tiro lets you measure your body-fat % trend with a 3D body scan and log measurements over time, so you can see your composition change without a clinic visit.

Which should you choose? Talk to your prescriber

If you came for a verdict on which drug to take, here's the honest one: that's not a decision to make on a muscle-loss stat. The "better" drug depends on tolerability, access and cost, insurance coverage, your medical history and your clinical goals — and it's a prescriber's call, informed by the FDA labels for each medication. In the UK, where tirzepatide (Mounjaro) is the dominant weight-loss brand and Zepbound isn't marketed, the same principle applies under NHS and NICE guidance: the choice is clinical, not something to self-select from an article.

What doesn't change with the drug is the muscle plan. Protein floor, resistance training, and measuring composition instead of just weight — that playbook is identical whether you're on Zepbound or Wegovy. Pick the medication with your clinician; keep the muscle either way.

If you're weighing the UK equivalents, see Mounjaro vs Ozempic and muscle loss. For dosing structure, here's the Zepbound dosage calculator and titration ladder, and for hitting your protein target, how many grams of protein per meal on Ozempic.

Frequently asked questions

Does Zepbound cause more muscle loss than Wegovy? The proportion of weight lost as lean mass appears broadly similar between the two. But because Zepbound (tirzepatide) tends to produce greater total weight loss than Wegovy (semaglutide) — about 20% versus 14% in SURMOUNT-5 — it can mean more absolute lean-mass loss. Both are largely preventable with adequate protein and resistance training.

How much protein should I eat on Zepbound or Wegovy to protect muscle? Muscle-preservation sources point to roughly 1.2–1.6 g/kg/day during weight loss (up from the ~0.8 g/kg general baseline), with some strength-training guidance reaching about 1.6–2.2 g/kg. A 90 kg person lands around 108–144 g/day, split across 3–4 meals of 20–40 g. Confirm your target with a dietitian or prescriber.

Is muscle loss on GLP-1 medications permanent? Generally no — lean mass can be preserved or rebuilt with enough protein and regular resistance training. The emphasis is on prevention during active weight loss rather than repair afterward. Discuss your plan with a prescriber or dietitian.

Where should I measure my body to track weight loss, not just the scale? Measure at fixed sites — waist, hips, thigh, upper arm and chest — and track a body-fat % trend plus progress photos. Re-measure monthly under the same conditions and watch the trend, not a single reading. A monthly 3D body scan can show a lean-versus-fat trend without a clinic visit.

Will I lose muscle if I'm only on the lowest (titration) dose? Risk tracks with the rate of weight loss and any protein shortfall more than the exact dose. The titration window matters because nausea — the most common GI side effect — tends to suppress protein intake right when it's needed. Front-load protein on stable-dose days, and raise persistent side effects with your prescriber. In Tiro you can log dose-timed side effects like nausea and get mitigation tips.

How do I know if I'm losing fat or muscle on Wegovy or Zepbound? You can't tell from the scale, which can't separate fat from muscle. Use a body-fat % trend, tape measurements at fixed sites, progress photos, or a 3D body scan to see whether the weight coming off is fat or lean.

Want the whole loop in one place — protein floor, dose reminders, side-effect logging and a body-fat % trend? See how Tiro works. Tiro is a tracker and companion, not a treatment; it doesn't change your clinical results, it helps you see and stay on top of them.

Sources

• Eli Lilly — Zepbound (tirzepatide) prescribing information
• Novo Nordisk — Wegovy (semaglutide) prescribing information
• SURMOUNT-5 head-to-head trial, New England Journal of Medicine (2025)
• SURMOUNT-1 (tirzepatide) body-composition data, New England Journal of Medicine
• STEP 1 (semaglutide) body-composition data, New England Journal of Medicine
• SURPASS program MRI muscle-composition analysis, The Lancet Diabetes & Endocrinology
• JAMA and peer-reviewed body-composition reviews on lean-mass loss during weight reduction
• International Society of Sports Nutrition (ISSN) position stand on protein and exercise
• U.S. Food and Drug Administration (FDA) drug labels for Zepbound and Wegovy
• NHS and NICE guidance (UK) on weight-management medication